Ronald C Petersen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6309328/publications.pdf

Version: 2024-02-01

		2309	1631
521	59,279	101	221
papers	citations	h-index	g-index

554	554	554	45257
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.4	7,498
2	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.9	4,117
3	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
4	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
5	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. New England Journal of Medicine, 2005, 352, 2379-2388.	13.9	1,709
6	Practice guideline update summary: Mild cognitive impairment. Neurology, 2018, 90, 126-135.	1.5	1,263
7	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.5	1,216
8	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.9	1,160
9	Mild Cognitive Impairment. New England Journal of Medicine, 2011, 364, 2227-2234.	13.9	1,032
10	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	18.1	784
11	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
12	Mild Cognitive Impairment as a Clinical Entity and Treatment Target. Archives of Neurology, 2005, 62, 1160.	4.9	773
13	Aging, Memory, and Mild Cognitive Impairment. International Psychogeriatrics, 1997, 9, 65-69.	0.6	758
14	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A caseâ€€control study. Alzheimer's and Dementia, 2015, 11, 600.	0.4	656
15	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology, 2008, 30, 58-69.	1.1	623
16	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
17	Neuropathologic Features of Amnestic Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 665.	4.9	562
18	Mild Cognitive Impairment:An Overview. CNS Spectrums, 2008, 13, 45-53.	0.7	548

#	Article	IF	Citations
19	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 39, 271-282.	1.2	540
20	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	3.8	493
21	Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO. Clinical Neuropsychologist, 1996, 10, 262-278.	1.5	477
22	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.4	420
23	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
24	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
25	Plasma phosphoâ€tau181 increases with Alzheimer's disease clinical severity and is associated with tauâ€• and amyloidâ€positron emission tomography. Alzheimer's and Dementia, 2018, 14, 989-997.	0.4	386
26	Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97. Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist, 1992, 6, 1-30.	1.4	374
27	Human whole genome genotype and transcriptome data for Alzheimerâ€™s and other neurodegenerative diseases. Scientific Data, 2016, 3, 160089.	2.4	361
28	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology, 2015, 85, 40-47.	1.5	355
29	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
30	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
31	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	3.8	311
32	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
33	Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	4.5	305
34	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
35	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.4	302
36	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	4.9	297

#	Article	IF	Citations
37	Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurology, 2016, 73, 93.	4.5	294
38	Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. Journal of Clinical Investigation, 2018, 128, 1208-1216.	3.9	289
39	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
40	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.4	266
41	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.4	261
42	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249
43	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	3.9	244
44	Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	4.9	241
45	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	4.5	235
46	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
47	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. Mayo Clinic Proceedings, 2014, 89, 1452-1459.	1.4	227
48	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
49	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
50	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
51	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	2.8	215
52	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.4	213
53	Early Diagnosis of Alzheimers Disease: Is MCI Too Late?. Current Alzheimer Research, 2009, 6, 324-330.	0.7	199
54	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199

#	Article	IF	Citations
55	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
56	TDP-43 represses cryptic exon inclusion in the FTDâ€“ALS gene UNC13A. Nature, 2022, 603, 124-130.	13.7	193
57	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 2013, 81, 1732-1740.	1.5	182
58	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182
59	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.4	181
60	Subjective cognitive decline and risk of MCI. Neurology, 2018, 91, e300-e312.	1.5	176
61	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
62	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of Neurology, 1998, 43, 303-310.	2.8	173
63	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	3.7	170
64	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
65	Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 769-773.	1.7	162
66	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
67	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. JAMA Neurology, 2014, 71, 1017.	4.5	160
68	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	4.5	160
69	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.5	160
70	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
71	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
72	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.4	157

#	Article	IF	Citations
73	Mild cognitive impairment clinical trials. Nature Reviews Drug Discovery, 2003, 2, 646-653.	21.5	155
74	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
75	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.4	155
76	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
77	Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	4.5	150
78	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurology, 2017, 74, 1073.	4.5	149
79	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 848-863.	1.5	149
80	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
81	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
82	Association of diabetes with amnestic and nonamnestic mild cognitiveÂimpairment. Alzheimer's and Dementia, 2014, 10, 18-26.	0.4	141
83	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	2.8	136
84	[¹⁸F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	2.2	136
85	Multimorbidity and Risk of Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2015, 63, 1783-1790.	1.3	135
86	Patterns and Predictors of Institutionalization in Communityâ€Based Dementia Patients. Journal of the American Geriatrics Society, 1994, 42, 181-185.	1.3	132
87	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
88	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
89	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
90	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. Clinical Neuropsychologist, 2013, 27, 1247-1264.	1.5	124

#	Article	IF	Citations
91	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
92	Selective loss of cortical endothelial tight junction proteins during Alzheimerâ€™s disease progression. Brain, 2019, 142, 1077-1092.	3.7	120
93	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
94	GWAS of longitudinal amyloid accumulation on¹⁸F-florbetapir PET in Alzheimerâ€™s disease implicates microglial activation geneIL1RAP. Brain, 2015, 138, 3076-3088.	3.7	117
95	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117
96	AGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE. Neurologic Clinics, 2000, 18, 789-805.	0.8	116
97	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
98	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970.	4.5	116
99	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.4	116
100	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
101	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	15.2	114
102	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
103	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
104	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.4	110
105	A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment. JAMA Neurology, 2014, 71, 581.	4.5	109
106	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
107	Mild Cognitive Impairment in Geriatrics. Clinics in Geriatric Medicine, 2018, 34, 563-589.	1.0	108
108	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a populationâ€based elderly cohort. Alzheimer's and Dementia, 2016, 12, 1226-1234.	0.4	107

#	Article	IF	Citations
109	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	4.5	107
110	Association of MAPT haplotypes with Alzheimerâ€™s disease risk and MAPT brain gene expression levels. Alzheimer's Research and Therapy, 2014, 6, 39.	3.0	106
111	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	0.8	106
112	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
113	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	4.9	104
114	Neuropsychiatric symptoms, APOE Îµ4, and the risk of incident dementia. Neurology, 2015, 84, 935-943.	1.5	101
115	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology, 2015, 84, 1433-1442.	1.5	101
116	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
117	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98
118	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
119	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
120	Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Human Genetics, 2001, 109, 646-652.	1.8	93
121	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
122	Association between tau deposition and antecedent amyloid-Î² accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	3.7	93
123	Î±-2 macroglobulin gene and Alzheimer disease. Nature Genetics, 1999, 22, 17-19.	9.4	91
124	Late-onset Alzheimerâ€™s risk variants in memory decline, incident mild cognitive impairment, and Alzheimerâ€™s disease. Neurobiology of Aging, 2015, 36, 60-67.	1.5	90
125	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
126	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89

#	Article	IF	Citations
127	Decline in Weight and Incident Mild Cognitive Impairment. JAMA Neurology, 2016, 73, 439.	4.5	89
128	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.4	88
129	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
130	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
131	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	1.2	86
132	Performance of the CogState computerized battery in the Mayo ClinicÂStudy on Aging. Alzheimer's and Dementia, 2015, 11, 1367-1376.	0.4	85
133	Selfâ€rated and informantâ€rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1080-1089.	0.4	85
134	No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement Disorders, 1995, 10, 566-573.	2.2	84
135	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiology of Aging, 2015, 36, 1245-1252.	1.5	83
136	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's and Dementia, 2018, 14, 1077-1087.	0.4	83
137	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
138	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimer's and Dementia, 2015, 11, 734-739.	0.4	80
139	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
140	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.4	79
141	Comparison of Gait Parameters forÂPredicting Cognitive Decline: TheÂMayoÂClinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	1.2	79
142	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	0.8	79
143	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	2.1	79
144	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76

#	Article	IF	Citations
145	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	4.4	75
146	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
147	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
148	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
149	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 225-234.	3.9	73
150	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
151	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	3.7	72
152	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.5	71
153	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE Îµ4 Genotype. JAMA Neurology, 2017, 74, 332.	4.5	71
154	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.5	70
155	Direct medical costs and source of cost differences across the spectrum of cognitive decline: A populationâ€based study. Alzheimer's and Dementia, 2015, 11, 917-932.	0.4	70
156	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	1.5	70
157	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
158	Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review. Mayo Clinic Proceedings, 2018, 93, 68-82.	1.4	69
159	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	4.5	69
160	Prosaposin is a regulator of progranulin levels and oligomerization. Nature Communications, 2016, 7, 11992.	5.8	68
161	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
162	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68

#	Article	IF	Citations
163	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	2.1	68
164	Spectrum of cognition short of dementia. Neurology, 2015, 85, 1712-1721.	1.5	67
165	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
166	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
167	Free and cued selective reminding test: Moans norms. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 676-691.	0.8	66
168	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	4.5	66
169	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 573-581.	1.2	65
170	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
171	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
172	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
173	Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurology: Genetics, 2015, 1, e15.	0.9	64
174	Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 177-188.	1.8	64
175	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
176	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
177	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
178	Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology, 2015, 84, 1854-1861.	1.5	61
179	Genome-wide, high-content siRNA screening identifies the Alzheimerâ€™s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathologica, 2017, 133, 955-966.	3.9	60
180	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60

#	Article	IF	Citations
181	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
182	How early can we diagnose Alzheimer disease (and is it sufficient)?. Neurology, 2018, 91, 395-402.	1.5	60
183	FOR DEBATE: IS MILD COGNITIVE IMPAIRMENT A CLINICALLY USEFUL CONCEPT?. International Psychogeriatrics, 2006, 18, 393.	0.6	59
184	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	2.1	59
185	Mild Cognitive Impairment Should Be Considered for DSM-V. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 147-154.	1.2	58
186	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
187	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57
188	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 11.	4.4	57
189	Alzheimer's disease: progress in prediction. Lancet Neurology, The, 2010, 9, 4-5.	4.9	56
190	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
191	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	3.3	55
192	Association of Mild Cognitive Impairment WithÂExposure to General Anesthesia for Surgical and Nonsurgical Procedures. Mayo Clinic Proceedings, 2016, 91, 208-217.	1.4	55
193	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
194	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54
195	Cortical Î²-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. Translational Psychiatry, 2019, 9, 123.	2.4	54
196	Nimodipine in the Treatment of Probable AlzheimerÊ¼s Disease. Clinical Drug Investigation, 1996, 11, 185-195.	1.1	53
197	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
198	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	0.6	52

#	Article	IF	Citations
199	A brief history of â€œAlzheimer diseaseâ€• Neurology, 2019, 92, 1053-1059.	1.5	52
200	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
201	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.4	51
202	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.5	51
203	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Annals of Neurology, 2017, 81, 871-882.	2.8	51
204	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	1.5	51
205	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
206	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
207	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
208	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. JAMA Neurology, 2014, 71, 201.	4.5	48
209	Frailty and Mortality Outcomes in Cognitively Normal Older People: Sex Differences in a Populationâ€Based Study. Journal of the American Geriatrics Society, 2016, 64, 132-137.	1.3	48
210	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
211	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.4	48
212	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
213	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	1.2	48
214	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	1.5	47
215	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
216	Primary progressive aphasia. Aphasiology, 1992, 6, 1-15.	1.4	46

#	Article	IF	Citations
217	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	3.0	45
218	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
219	Influence of amyloid and APOE on cognitive performance in a late middleâ€aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291.	0.4	45
220	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
221	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
222	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
223	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 2311.	5.8	44
224	Association of plasma and cortical amyloid beta is modulated by APOE Î¼4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.4	43
225	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	1.1	42
226	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNFÎ± and Cognitive Outcomes in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1289-1295.	1.7	42
227	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 45, 1237-1245.	1.2	41
228	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
229	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
230	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	1.3	41
231	Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	2.8	41
232	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2019, 15, 878-887.	0.4	41
233	Mild Cognitive Impairment: Is it Alzheimer's disease or Not?. Journal of Alzheimer's Disease, 2005, 7, 241-245.	1.2	40
234	Evaluation of memory endophenotypes for association with CLU , CR1, and PICALM variants in black and white subjects. , 2014, 10, 205-213.		40

#	Article	IF	Citations
235	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
236	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
237	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	2.8	40
238	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
239	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
240	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	4.5	39
241	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
242	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. Neurology, 2019, 93, e548-e558.	1.5	38
243	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	1.5	38
244	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38
245	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	3.7	38
246	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37
247	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
248	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
249	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	1.4	36
250	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
251	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616.	1.2	35
252	Randomized controlled trials in mild cognitive impairment. Neurology, 2017, 88, 1751-1758.	1.5	35

#	Article	IF	Citations
253	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	1.4	35
254	Age and education corrected older adult normative data for a short form version of the Financial Capacity Instrument.. Psychological Assessment, 2016, 28, 737-749.	1.2	35
255	Short and long telomeres increase risk of amnestic mild cognitive impairment. Mechanisms of Ageing and Development, 2014, 141-142, 64-69.	2.2	34
256	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
257	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
258	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1372-1383.	0.4	34
259	[P2â€“415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.4	33
260	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2018, 63, 149-155.	1.2	33
261	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
262	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
263	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30â€“91 Years and the Importance of Adjusting for Sex. Journal of the International Neuropsychological Society, 2021, 27, 211-226.	1.2	33
264	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
265	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
266	Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies. Neurobiology of Aging, 2018, 69, 111-116.	1.5	32
267	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	2.8	32
268	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	3.0	32
269	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
270	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31

#	Article	IF	Citations
271	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
272	International drive to illuminate delirium: A developing public health blueprint for action. Alzheimer's and Dementia, 2020, 16, 711-725.	0.4	31
273	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	2.8	31
274	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
275	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2018, 66, 68-74.	1.5	30
276	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	1.7	30
277	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
278	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	1.4	30
279	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
280	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29
281	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	1.0	29
282	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
283	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
284	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 301-304.	1.8	28
285	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
286	Risk Factors for Persistent Cognitive Impairment After Critical Illness, Nested Case-Control Study. Critical Care Medicine, 2018, 46, 1977-1984.	0.4	28
287	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.5	28
288	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2022, 18, 635-644.	0.4	28

#	Article	IF	Citations
289	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
290	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
291	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084.	1.5	27
292	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
293	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	1.1	27
294	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	1.5	27
295	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27
296	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
297	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
298	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
299	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.4	26
300	Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. , 2016, 12, 598-603.		26
301	ABCA7 loss-of-function variants, expression, and neurologic disease risk. Neurology: Genetics, 2017, 3, e126.	0.9	26
302	Contributions of imprecision in <scp>PET</scp>â€<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	1.9	26
303	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
304	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. Scientific Reports, 2020, 10, 3869.	1.6	26
305	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
306	Neurocognition in individuals with incidentally-identified meningioma. Journal of Neuro-Oncology, 2017, 134, 125-132.	1.4	25

#	Article	IF	Citations
307	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the populationâ€based Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2018, 33, 1114-1120.	1.3	25
308	Population-Based Evaluation of Lumbar Puncture Opening Pressures. Frontiers in Neurology, 2019, 10, 899.	1.1	25
309	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimerâ€™s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 261-274.	1.2	25
310	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	1.7	25
311	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. American Journal of Geriatric Psychiatry, 2021, 29, 179-191.	0.6	25
312	Mild Cognitive Impairment: Where Are We?. Alzheimer Disease and Associated Disorders, 2005, 19, 166-169.	0.6	24
313	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
314	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
315	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
316	Diabetes is Associated with Worse ExecutiveÂFunction in Both Eastern andÂWestern Populations: Shanghai Aging Study andÂMayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 47, 167-176.	1.2	23
317	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
318	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	1.1	23
319	Timing of Physical Activity, Apolipoprotein E Îµ4 Genotype, and Risk of Incident Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2016, 64, 2479-2486.	1.3	23
320	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	1.2	23
321	Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE Îµ4 allele. Alzheimer's and Dementia, 2020, 16, 598-609.	0.4	23
322	Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223.	0.4	23
323	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2015, 11, 1069-1079.	0.4	22
324	First PET Imaging Studies With ⁶³Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. Molecular Imaging, 2016, 15, 153601211667379.	0.7	22

#	Article	IF	Citations
325	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
326	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	1.1	22
327	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290.	1.2	22
328	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
329	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
330	Mild cognitive impairment: Useful or not?. , 2005, 1, 5-10.		20
331	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
332	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	0.7	20
333	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. Critical Care Medicine, 2019, 47, 1116-1124.	0.4	20
334	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.4	20
335	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.4	20
336	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
337	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19
338	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
339	Plasma Sphingolipids are Associated With Gait Parameters in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 960-965.	1.7	19
340	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
341	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
342	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19

#	Article	IF	Citations
343	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
344	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. Neurology, 2020, 94, e1571-e1579.	1.5	18
345	Association of Hospitalization with Longâ€Term Cognitive Trajectories in Older Adults. Journal of the American Geriatrics Society, 2021, 69, 660-668.	1.3	18
346	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	2.4	18
347	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18
348	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
349	Deep Learning Prediction of Mild Cognitive Impairment using Electronic Health Records. , 2019, 2019, 799-806.		17
350	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
351	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
352	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
353	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
354	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
355	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.4	17
356	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2023, 19, 4498-4506.	0.4	17
357	Mild Cognitive Impairment: Transition from Aging to Alzheimer's Disease. , 0, , 141-151.		16
358	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
359	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	0.9	16
360	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 877-883.	1.7	16

#	Article	IF	Citations
361	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2021, 36, 1362-1369.	1.3	16
362	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 T	0.4	16
363	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.5	15
364	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study ofÂAging. Journal of Alzheimer's Disease, 2017, 58, 1273-1281.	1.2	15
365	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
366	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
367	Conversion. Neurology, 2006, 67, S12-3.	1.5	15
368	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
369	The current status of mild cognitive impairmentâ€"what do we tell our patients?. Nature Clinical Practice Neurology, 2007, 3, 60-61.	2.7	14
370	Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. Experimental Gerontology, 2016, 84, 96-100.	1.2	14
371	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-Î²42 in Alzheimerâ€™s disease. Brain, 2017, 140, 3301-3316.	3.7	14
372	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14
373	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602.	1.5	14
374	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.5	14
375	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
376	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
377	A longitudinal investigation of AÎ², anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831.	0.4	14
378	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14

#	Article	IF	Citations
379	Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimerâ€™s pathophysiology and susceptibility. Molecular Neurodegeneration, 2015, 10, 18.	4.4	13
380	Decreased Expression of Sulfatase 2 in the Brains of Alzheimerâ€™s Disease Patients: Implications for Regulation of Neuronal Cell Signaling. Journal of Alzheimer's Disease Reports, 2017, 1, 115-124.	1.2	13
381	Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging. Experimental Gerontology, 2018, 106, 67-73.	1.2	13
382	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. Age and Ageing, 2019, 48, 888-894.	0.7	13
383	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	1.5	13
384	Cognitive function after surgery with regional or general anesthesia: A populationâ€based study. Alzheimer's and Dementia, 2019, 15, 1243-1252.	0.4	13
385	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
386	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. Clinical Neuropsychologist, 2019, 33, 1102-1126.	1.5	13
387	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
388	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
389	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	1.5	13
390	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
391	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
392	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
393	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
394	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	1.5	12
395	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 79, 377-388.	1.2	12
396	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12

#	Article	IF	Citations
397	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	1.5	12
398	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
399	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. NeuroImage: Clinical, 2019, 21, 101574.	1.4	11
400	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.4	11
401	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
402	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	1.5	11
403	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
404	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	1.8	10
405	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	1.3	10
406	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
407	Aducanumab: What about the Patient?. Annals of Neurology, 2021, 90, 334-335.	2.8	10
408	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
409	Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's and Dementia, 2022, 18, 2603-2613.	0.4	10
410	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
411	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE Îµ4 genotype status: the Mayo Clinic Study of Aging. European Journal of Ageing, 2019, 16, 491-502.	1.2	9
412	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.2	9
413	Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 64-71.	0.9	9
414	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9

#	Article	IF	Citations
415	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
416	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	1.1	8
417	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. JAMA - Journal of the American Medical Association, 2019, 321, 1258.	3.8	8
418	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2019, 33, 68-71.	0.6	8
419	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	2.4	8
420	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	2.4	8
421	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
422	Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. Journal of Alzheimer's Disease, 2021, 83, 915-925.	1.2	8
423	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. Journal of Alzheimer's Disease, 2021, 83, 1269-1279.	1.2	8
424	Do preclinical Alzheimer's disease criteria work?. Lancet Neurology, The, 2013, 12, 933-935.	4.9	7
425	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
426	Creating three dimensional models of Alzheimerâ€™s disease. 3D Printing in Medicine, 2017, 3, 13.	1.7	7
427	Effect of Cognitive Status on the Receipt of Procedures Requiring Anesthesia and Critical Care Admissions in Older Adults. Mayo Clinic Proceedings, 2018, 93, 1552-1562.	1.4	7
428	Factors Associated With Meningioma Detected in a Population-Based Sample. Mayo Clinic Proceedings, 2019, 94, 254-261.	1.4	7
429	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2019, 79, 43-49.	1.5	7
430	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	1.1	7
431	Brain MRI after critical care admission: A longitudinal imaging study. Journal of Critical Care, 2021, 62, 117-123.	1.0	7
432	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7

#	Article	IF	Citations
433	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. Journal of Alzheimer's Disease, 2021, 83, 861-877.	1.2	7
434	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	1.5	7
435	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
436	Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. Neurology, 2022, 98, .	1.5	7
437	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE Îµ4 Allele. Frontiers in Aging Neuroscience, 2015, 7, 172.	1.7	6
438	The Human Alzheimer Disease Project. JAMA Neurology, 2015, 72, 626.	4.5	6
439	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a populationâ€based sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 127-130.	1.2	6
440	Poly (ADP-Ribose) and Î±â€“synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	1.1	6
441	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
442	Artificial Intelligenceâ€“Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
443	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
444	Cardiorespiratory Fitness and Brain Volumes. Mayo Clinic Proceedings, 2020, 95, 6-8.	1.4	5
445	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	1.1	5
446	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. German Journal of Exercise and Sport Research, 2021, 51, 487-494.	1.0	5
447	MCI Criteria in ADNI. Neurology, 2021, 97, 597-599.	1.5	5
448	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
449	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
450	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4

#	Article	IF	Citations
451	Clinical Deep Phenotyping of ABCA7 Mutation Carriers. Neurology: Genetics, 2022, 8, e655.	0.9	4
452	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
453	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldtâ€“Jakob disease and autoimmune encephalitis. European Journal of Neurology, 2022, 29, 2905-2912.	1.7	4
454	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2020, 78, 911-917.	1.2	3
455	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	1.5	3
456	Brain amyloid, cortical thickness, and changes in activities of daily living. Annals of Clinical and Translational Neurology, 2020, 7, 474-485.	1.7	3
457	Association between surgery with anesthesia and cognitive decline in older adults: Analysis using shared parameter models for informative dropout. Journal of Clinical and Translational Science, 2021, 5, e27.	0.3	3
458	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	2.1	3
459	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 81, 533-543.	1.2	3
460	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
461	Early Alert of Elderly Cognitive Impairment using Temporal Streaming Clustering. , 2021, 2021, 905-912.		3
462	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	3.9	3
463	IC-03-01: Early MCI as an imaging target: Data from the National Alzheimer's Coordinating Center. , 2010, 6, S58-S58.		2
464	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	1.5	2
465	Nursing Home Use Across The Spectrum of Cognitive Decline: Merging Mayo Clinic Study of Aging With CMS MDS Assessments. Journal of the American Geriatrics Society, 2017, 65, 2235-2243.	1.3	2
466	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	0.9	2
467	Preoperative cognitive impairment associated with oversedation during recovery from anesthesia. Journal of Anesthesia, 2020, 34, 390-396.	0.7	2
468	The quest for dementia prevention does not include an aspirin a day. Neurology, 2020, 95, 105-106.	1.5	2

#	Article	IF	Citations
469	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625.	1.2	2
470	Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy. Alzheimer's and Dementia, 2008, 4, S88-90.	0.4	1
471	Commentary on â€œA roadmap for the prevention of dementia II: Leon Thal Symposium 2008.â€•A national registry on aging. , 2009, 5, 105-107.		1
472	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	0.7	1
473	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e272-e280.	1.7	1
474	Medical and nursing home costs: From cognitively unimpaired through dementia. Alzheimer's and Dementia, 2021, , .	0.4	1
475	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2020, 93, 52-54.	1.5	1
476	Connecting Cohorts to Diminish Alzheimerâ€™s Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	1.2	1
477	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	1.2	1
478	Where Do We Go from Here?. journal of prevention of Alzheimer's disease, The, 2022, 9, 188-189.	1.5	1
479	Are plasma markers for Alzheimerâ€™s disease ready for clinical use?. Nature Aging, 2022, 2, 94-96.	5.3	1
480	Detecting Alzheimer Disease Clinically. Neurology, 2022, 98, 607-608.	1.5	1
481	CSF and blood plasma mass spectrometry measures of AÎ², tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
482	The screening and enrollment of underrepresented ethnoracial and educational populations in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2021, 17, .	0.4	1
483	Prediction of Incident Dementia Using Patient Temporal Health Status. Studies in Health Technology and Informatics, 2022, , .	0.2	1
484	Mild cognitive impairment. , 2005, , 409-415.		0
485	Commentary on â€œDiagnosis of Alzheimer's disease: Two decades of progressâ€• , 2005, 1, 122-123.		0
486	F5-04-04: Scd in a population-based sample: Progression to MCI. , 2015, 11, P308-P309.		0

#	Article	IF	Citations
487	FTS3â€03â€01: The U.S. National Alzheimerâ€™s Plan: Five Years Later. Alzheimer's and Dementia, 2016, 12, P278.	0.4	0
488	[P1â€“393]: PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDGâ€PET IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P418.	0.4	0
489	[ICâ€Pâ€204]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P149.	0.4	0
490	[F4â€“03â€“04]: INTERVENTIONS FOR PREVENTING COGNITIVE DECLINE AND DEMENTIA: RECOMMENDATIONS FROM A NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY. Alzheimer's and Dementia, 2017, 13, P1214.	0.4	0
491	P2â€491: SUBTLE COGNITIVE DYSFUNCTION ON COGSTATE IS ASSOCIATED WITH BIOMARKER POSITIVE STATUS. Alzheimer's and Dementia, 2018, 14, P917.	0.4	0
492	P3â€221: LONGITUDINAL ASSOCIATION BETWEEN PHOSPHATIDYLCHOLINES, NEUROIMAGING MEASURES OF ALZHEIMER'S DISEASE PATHOPHYSIOLOGY, AND COGNITION IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1156.	0.4	0
493	P3â€238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOIDâ€PET, FDGâ€PET, AND COGNITION AMONG NONâ€DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1163.	0.4	0
494	P1â€532: MEASURING LATENT COGNITIVE PROCESSES TO DETECT THE EARLIEST CHANGES IN AD. Alzheimer's and Dementia, 2018, 14, P536.	0.4	0
495	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782.	0.4	0
496	P4â€078: CONCORDEâ€AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1465.	0.4	0
497	ICâ€Pâ€144: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDGâ€PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM. Alzheimer's and Dementia, 2018, 14, P122.	0.4	0
498	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P603.	0.4	0
499	P1â€160: ABI3 AND PLCG2 AS RISK FACTORS FOR ALZHEIMER'S DISEASE IN CAUCASIANS AND AFRICAN AMERICANS. Alzheimer's and Dementia, 2018, 14, P339.	0.4	0
500	O2â€13â€01: INCIDENCE OF CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P652.	0.4	0
501	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
502	ICâ€Pâ€083: DIAGNOSTIC UTILITY OF [18F]AVâ€1451 PET, FDGâ€PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA. Alzheimer's and Dementia, 2018, 14, P71.	0.4	0
503	ICâ€Pâ€019: LONGITUDINAL ACCUMULATION OF Î²â€AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P25.	0.4	0
504	P1â€414: STATINS AND BRAIN HEALTH: MEDICATION EFFECTS ON NEUROIMAGING BIOMARKERS IN OLDER INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P463.	0.4	0

#	Article	IF	Citations
505	FTS3â€01â€03: U.S. PERSPECTIVE ON CLINICAL AMYLOID IMAGING. Alzheimer's and Dementia, 2018, 14, P1004.	0.4	0
506	P1â€387: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDGâ€PET BASED UNSUPERVISED MACHINE LEARNING ALGORITHM. Alzheimer's and Dementia, 2018, 14, P449.	0.4	0
507	P3â€597: MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE. Alzheimer's and Dementia, 2018, 14, P1356.	0.4	0
508	P3â€424: LONGITUDINAL ACCUMULATION OF Î²â€AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1271.	0.4	0
509	P3â€202: TDPâ€43 IN ATYPICAL ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1145.	0.4	0
510	P2â€407: COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION. Alzheimer's and Dementia, 2018, 14, P863.	0.4	0
511	ICâ€Pâ€086: CORTICAL ATROPHY PATTERNS OF EMPIRICALLY DERIVED INCIDENT MCI SUBTYPES IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2019, 15, P76.	0.4	0
512	ICâ€Pâ€022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGINGâ€ALZHEIMER'S CONTINUUM. Alzheimer's and Dementia, 2019, 15, P30.	0.4	0
513	NIAâ€AA AD framework stage 2: Performance in the community. Alzheimer's and Dementia, 2020, 16, e040262.	0.4	0
514	Medical Doctors and Dementia: A Longitudinal Study. Journal of the American Geriatrics Society, 2020, 68, 1250-1255.	1.3	0
515	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. Journal of Magnetic Resonance Imaging, 2022, 55, 1907-1909.	1.9	0
516	Reply to â€œThinking beyond Aducanumab Controversyâ€• Annals of Neurology, 2021, 90, 1004-1004.	2.8	0
517	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 304-313.	1.7	0
518	Reply to A Letter Concerning â€œAducanumab: What About the Patient?â€• Annals of Neurology, 2022, 91, 733-734.	2.8	0
519	The Overlap Index: A new means for early detection of serial tau PET signal change. Alzheimer's and Dementia, 2021, 17, .	0.4	0
520	Diffusion models reveal white matter microstructural changes with aging, pathology, and cognition. Alzheimer's and Dementia, 2021, 17, .	0.4	0
521	Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population. Alzheimer's and Dementia, 2021, 17, .	0.4	0